Código QR

The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis

<b>Background</b>: A glioblastoma (GBM) is a type of tumor originating from the glial brain cells, the astrocytes, and thus belongs to the astrocytoma group. Bevacizumab (BV) is a treatment for GBM. BV is the active ingredient in the drugs Avastin<sup>®</sup>, Alymsys<sup>®</sup>, Mvasi<sup>®</sup>...

Descrición completa

Gardado en:
Principais autores: Alejandro Bruna-Mejías, Vicente Silva-Bravo, Laura Moyano Valarezo, María Fernanda Delgado-Retamal, Diego Nazar-Izquierdo, Isidora Aguilar-Aguirre, Pablo Nova-Baeza, Mathias Orellana-Donoso, Alejandra Suazo-Santibáñez, Héctor Gutiérrez-Espinoza, Juan Sanchis Gimeno, Carlos Bastidas-Caldes, Juan José Valenzuela Fuenzalida
Formato: Artigo
Idioma:Inglês
Publicado: MDPI AG 2025-05-01
Series:Pharmaceuticals
Assuntos:
bevacizumab therapy
bevacizumab pharmaceutical
glioblastoma
multiform glioblastoma
glioma
Acceso en liña:https://www.mdpi.com/1424-8247/18/6/795
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares